Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy
Key facts
- Who runs it
- Byron Lam
- Where
- Miami, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 28 people enrolled
- Started
- 14 Jul 2014
- Ended
- 31 Mar 2025
- Type of study
- Interventional, 4 groups
- Treatments tested
- injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),
- injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)
- injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)
- injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)
- Record updated
- 5 June 2025
Who can take part
- Age
- 15 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age 15 or older
- Patients with LHON and the G11778A mitochondrial DNA mutation. A previous CLIA-certified genetic lab result showing the LHON G11778A mutation will be accepted for inclusion
- Ability to perform tests of visual and retinal function
- Ability to comply with research procedures
- Able and willing to provide informed consent before undergoing any study-related procedures
- Good general health as based on the investigator's assessment of the history, physical examination, and laboratory testing performed at the baseline examination
Who cannot take part
- Optic disc drusen on exam or in previous history
- Previous eye surgery in the eye selected for injection
- Ocular diseases or visual dysfunction conditions other than refractive error (e.g. amblyopia, glaucoma, etc.) in the eye selected for the injection
- Type I diabetes or the presence of diabetic retinopathy
- History of neurodegenerative conditions (e.g. multiple sclerosis, neuromyelitis optica, Parkinson's disease)
- History of autoimmune conditions (e.g. systemic lupus erythematosus)
- Systemic diseases having ocular manifestations likely to confound assessment of study results. History of cancer within five years other than localized basal or squamous cell carcinoma not near the orbital area. Patients with a prior history of cancer will need documentation from their cancer specialist that the cancer was cured at least 5 years before study entry
- Allergy to pupil dilating drops or narrow angles precluding safe dilation
- Aspartate transaminase (AST)/alanine transaminase (ALT) >5.0 x upper limit of normal (ULN); Total bilirubin >3 x ULN; Hemoglobin < 8 g/dL; neutrophil count <1.0 x 109/L; or platelet count < 50 x 109/L; Any laboratory screening test that meets the abnormality criteria stated above can be repeated once between Baseline one to Baseline 2
- Unwilling or unable to give consent,
- Unable or unlikely to return for scheduled protocol visits
- Pregnant or nursing women or unwillingness for subject with childbearing potential to use contraception during the first year of the study
- No Light Perception (NLP) vision in either eye
Where in United States
- Bascom Palmer Eye Institute - University of MiamiMiami, United States
About the trial
What the trial wants to find out
The study is a dose-escalation study, phase 1. The objective of this proposed clinical trial is to evaluate the safety of mitochondrially targeted ND4 gene therapy with the adeno-associated viral vector in appropriate LHON patients.
The 4 groups in the trial
- Low-dose (1.18x10e9 vg)Treatment being tested
Participants with Chronic Bilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 1.18x10e9 vg. Participants with Acute Bilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 1.18x10e9 vg. Participants with Acute Unilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 1.18x10e9 vg
Treatment: injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),
- Medium dose (5.81x10e9 vg)Treatment being tested
Participants with Chronic Bilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 5.81x10e9 vg. Participants with Acute Bilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 5.81x10e9 vg. Participants with Acute Unilateral Severe Vision Loss were administered 200 µL of scAAV2-P1ND4v2 containing a dose of 5.81x10e9 vg.
Treatment: injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)
- High dose (2.40x10e10 vg)Treatment being tested
Participants with Chronic Bilateral Severe Vision Loss were administered 100 µL of scAAV2-P1ND4v2 containing a dose of 2.40x10e10 vg.
Treatment: injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)
- Higher dose (1x10e11vg)Treatment being tested
Participants with Chronic Bilateral Severe Vision Loss were administered 100 µL of scAAV2-P1ND4v2 containing a dose of 1x10e11vg. Participants with Acute Bilateral Severe Vision Loss were administered 100 µL of scAAV2-P1ND4v2 containing a dose of 1x10e11vg. Participants with Acute Unilateral Severe Vision Loss were administered 100 µL of scAAV2-P1ND4v2 containing a dose of 1x10e11vg.
Treatment: injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA
- Record updated
- 5 June 2025